收费全文 | 746588篇 |
免费 | 38867篇 |
国内免费 | 871篇 |
医药卫生 | 786326篇 |
2021年 | 7159篇 |
2019年 | 7547篇 |
2018年 | 12697篇 |
2017年 | 8732篇 |
2016年 | 9476篇 |
2015年 | 10466篇 |
2014年 | 12449篇 |
2013年 | 19095篇 |
2012年 | 30646篇 |
2011年 | 32519篇 |
2010年 | 17484篇 |
2009年 | 14373篇 |
2008年 | 28667篇 |
2007年 | 31246篇 |
2006年 | 29639篇 |
2005年 | 28843篇 |
2004年 | 27647篇 |
2003年 | 25997篇 |
2002年 | 24919篇 |
2001年 | 27767篇 |
2000年 | 28405篇 |
1999年 | 23760篇 |
1998年 | 6015篇 |
1997年 | 5035篇 |
1996年 | 5028篇 |
1995年 | 4713篇 |
1992年 | 17291篇 |
1991年 | 18427篇 |
1990年 | 18444篇 |
1989年 | 17931篇 |
1988年 | 16477篇 |
1987年 | 16237篇 |
1986年 | 15104篇 |
1985年 | 14445篇 |
1984年 | 10681篇 |
1983年 | 9109篇 |
1982年 | 4803篇 |
1979年 | 10067篇 |
1978年 | 7169篇 |
1977年 | 5874篇 |
1976年 | 6083篇 |
1975年 | 7349篇 |
1974年 | 8337篇 |
1973年 | 8066篇 |
1972年 | 7450篇 |
1971年 | 7156篇 |
1970年 | 6655篇 |
1969年 | 6300篇 |
1968年 | 5899篇 |
1967年 | 5251篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献